Trial Profile
A study evaluating role of whole body-Magnetic Resonance Imaging in early detection of thromboembolic events in Paroxysmal Nocturnal Hemoglobinuria patients treated with eculizumab .
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Diagnostic use
- 10 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology